Background: Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of atopic dermatitis (AD).
Atopic dermatitis (AD) is a chronic, complex inflammatory skin condition that is characterized by pruritic eczematous skin lesions, impacting patients' and their families' quality of life. [1] [2] [3] Patients with mild AD can usually control their condition by avoiding disease triggers and applying emollients and topical corticosteroids (TCS). 4 AD onset is often accompanied by other allergic disease manifestations 5 and, as recently identified, is associated with an increased risk of cardiovascular disease versus patients without AD, 6 suggesting that the condition is a complex systemic disorder. Patients with moderate to severe AD may benefit from systemic therapy 4, 7, 8 ; however, more robust studies are required to evaluate their efficacy and long-term safety. 9 Thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine, is produced in response to proinflammatory stimuli. TSLP-activated dendritic cells induce production of T helper 2-type (T H 2) cytokines, interleukins (IL)-4, -5, and -13 and tumor necrosis factorea. 10 Increasing evidence supports a role for T H 2 inflammation in AD pathogenesis [11] [12] [13] [14] [15] [16] [17] ; recent studies of dupilumab (an IL-13/-4 inhibitor) demonstrated substantial responses in patients with AD. TSLP could be a key target to control AD-associated inflammation and skin barrier disruption, the pathogenesis of which is associated with these downstream T H 2 cytokines and immunomodulating proteins. Serum periostin and dipeptidyl peptidase-4 (DPP-4) are considered biomarkers of IL-13 axis activation 18, 19 and may predict response to molecules targeting TSLP, which is upstream of IL-13. 10 Similarly, immunoglobulin E (IgE) and chemokine (C-C motif) ligand 17/thymus-and activation-regulated chemokine (CCL17/TARC) are upregulated by TSLP 10, 20 and could reflect increased TSLP activity.
Tezepelumab (AMG 157/MEDI9929) is a first-inclass, fully human immunoglobulin G2l monoclonal antibody that specifically binds TSLP and prevents interaction with its receptor complex. In the phase 2b PATHWAY study, tezepelumab demonstrated significant reductions in annual asthma exacerbation rate versus placebo in patients with uncontrolled asthma, irrespective of baseline biomarker status.
We evaluate the efficacy and safety of tezepelumab in patients with moderate to severe AD who were treated with continuous concomitant class 3 21 TCS. The effects of tezepelumab in patient-reported outcomes and impact of serum biomarkers on treatment response are also reported.
METHODS

Study design
This phase 2a, randomized, double-blind, placebocontrolled study (ALLEVIAD; NCT02525094) was conducted at 26 centers in Australia, Canada, Germany, Hungary, New Zealand, and the United States, in accordance with the Declaration of Helsinki, International Conference on Harmonization guidelines, and relevant laws and regulations. The protocol and amendments were approved by appropriate institutional review boards and independent ethics committees. Written informed consent was obtained from all patients.
Eligible patients received maintenance class 3 (high-strength) TCS at least once daily on lesional skin during the 2-week run-in period and throughout the 24-week study. Patients were stratified at randomization by their screening serum IgE concentration (\150 or $150 kU/L). Within each stratum, patients were randomized 1:1 (via central interactive voice/web response) to receive placebo or tezepelumab 280 mg subcutaneously every 2 weeks for 12 weeks; the last dose was at week 10. Patients completed a 10-week safety follow-up period. Randomization, treatment administration, blinding methodology, and study termination guidelines are provided in the supplement (available at: https://astrazenecagrouptrials.pharm acm.com/ST/Submission/View?id=22659).
Patients
Eligible patients were 18 to 75 years of age and had a diagnosis of AD (according to the criteria established by Hanifin and Rajka), an Eczema Area and Severity Index (EASI) score $12 and Investigator's Global Assessment (IGA) score $3 (screening and baseline), a Scoring of Atopic Dermatitis (SCORAD) $20, and total AD body surface area $10% as assessed by EASI (screening 
Study endpoints
The primary efficacy endpoint was the percentage of patients achieving a $50% reduction in EASI score (EASI50) from baseline to week 12. Secondary endpoints (including patient-reported outcomes) and exploratory endpoints were measured at week 12; the full details are provided in the supplement (available at: https://astrazenecagrouptrials.pharmacm.com/ST/ Submission/View?id=22659). A post hoc analysis of all endpoints was conducted at week 16.
Safety endpoints measured through week 22 included treatment-emergent adverse events (TEAEs) and serious TEAEs (TESAEs). In an exploratory analysis, selected endpoints were evaluated in subgroups, defined by inflammatory markers of pathways downstream of TSLP: serum periostin, DPP-4, and CCL17/TARC, and IgE. The clinical assessments performed and methods for serum biomarker determination are detailed in the supplement (available at: https:// astrazenecagrouptrials.pharmacm.com/ST/Submission/ View?id=22659).
Statistical methods
Based on a previous study, it was estimated that a sample size of 25 patients per treatment group would provide 80% power (2-sided significance of .05) to detect a treatment difference of 40% for the primary endpoint, assuming a placebo response rate of 45%. The biomarker subpopulation was assumed to be 50% of the total population, and sample size was adjusted by doubling the required number to 50 patients per treatment group.
Efficacy endpoints were analyzed in the intention-to-treat population, defined as all patients who were randomized to and received treatment; data were grouped by randomized treatment. Safety data were reported in the as-treated population, defined as all patients who received treatment, with data grouped by first treatment received.
Baseline demographics and safety data were summarized descriptively. Binary endpoints were analyzed at each visit using logistic regression with total serum IgE concentration and baseline value as covariates. The last nonmissing postbaseline value was carried forward when data were missing. For patients who received prohibited or discouraged AD treatment, the last response value from the day of or before receipt of the therapy was carried forward. Continuous endpoints were analyzed using a mixed-effect model repeated-measure analysis. No multiplicity adjustments were made for secondary or exploratory analyses. Exploratory analyses of biomarker data were not powered, but were prespecified and used similar statistical methods for the primary analysis.
RESULTS
Patients
The first patient was screened on August 15, 2015, and the first patient dosed on August 29, 2015. The last patient was evaluated on July 15, 2016. Of 155 patients screened, 113 were randomized and 111 received treatment (placebo plus TCS: N = 56; tezepelumab plus TCS: N = 55; Fig 1) . Baseline demographics and clinical characteristics were similar between treatment groups (Table I) . In both groups, 84.7% of patients had childhood AD, 43.2% had childhood asthma, and 39.6% had adult asthma. At the end of the treatment period, tezepelumab-treated patients had applied fewer 
Efficacy outcomes
At week 12, a numerically greater percentage of tezepelumab plus TCS-treated patients achieved an EASI50 response (64.7%) compared with placebo plus TCS (48.2%); however, the treatment difference was not statistically significant (odds ratio [OR] [95% confidence interval {CI}]) 1.97 (0.90-4.33); P = .091; Fig 2, A) Fig 2, A) . A post hoc analysis of change in lichenification (measured through EASI and SCORAD scoring) found no significant difference between treatment groups at any time point (Supplemental Table S1 , available at: https:// astrazenecagrouptrials.pharmacm.com/ST/Submission/ View?id=22659). Improvements in adjusted mean percentage improvement from baseline in EASI (total score) relative to placebo plus TCS were observed from week 4 and maintained until week 16 in tezepelumab plus TCS-treated patients (Fig 2, B) . Fig 2, C ) .
Numerical improvements in SCORAD versus placebo were observed throughout the analysis period (Fig 2, D) 
Safety assessments
The safety analysis was performed on the as-treated population (N = 111). One patient randomized to placebo received an incorrect first dose of tezepelumab and was included in the tezepelumab group; all subsequent doses were placebo.
The incidence of TEAEs was similar between treatment groups (Table II) . Most were mild or moderate in severity (grade 1/2), while 5 (8.9%) tezepelumab plus TCS-treated and 7 (12.7%) placebo plus TCS-treated patients experienced a TESAE ($grade 3). No deaths were reported. The most frequent TEAE that was considered by the investigators to be possibly treatment-related was injection-site erythema, which was reported in 3 (5.4%) patients receiving tezepelumab and no placebo plus TCS-treated patients. One placebo plus TCS-treated patient experienced a treatmentrelated TESAE of cellulitis.
Six patients discontinued treatment because of TEAEs; all events were unrelated to study treatment. Placebo plus TCS-treated patients experienced AD worsening (n = 3) and eczema flare (n = 1), while tezepelumab plus TCS-treated patients reported AD worsening (n = 1) and vasovagal syncope (n = 1).
Exploratory biomarker subgroup analyses
Tezepelumab plus TCS-treated patients who were DPP-4ehigh, periostin-low, CCL17/TARC-low, or IgE-high had numerically greater week 12 responses compared with opposing biomarker subgroups. 
DISCUSSION
Subcutaneous tezepelumab 280 mg every 2 weeks plus TCS did not demonstrate statistically significant improvements in patients with moderate to severe AD versus placebo plus TCS, as assessed by EASI50 at week 12. A trend toward improvement for tezepelumab plus TCS-treated patients versus placebo plus TCS was observed for almost all endpoints. At week 16, a trend toward a superior EASI75 response and stronger improvement in IGA response in tezepelumab plus TCS-treated patients versus placebo plus TCS was observed. Patients were considered to be IGA responders if they had an IGA response of 0 or 1 and a reduction of $2 grades from baseline to week 12. IGA severity categories are 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). *Nominal P \ .05 for the comparison with placebo. EASI50, A $50% reduction in Eczema Area and Severity Index score; EASI75, a $75% reduction in Eczema Area and Severity Index score; EASI90, a $90% reduction in Eczema Area and Severity Index score; IGA, Investigator's Global Assessment; ITT, intention-to-treat; SCORAD, Scoring of Atopic Dermatitis; SE, standard error; TCS, topical corticosteroids. The limited efficacy demonstrated on inflammatory signs and itch via TSLP blockade is surprising because preclinical studies implicate a role for TSLP in AD. In AD mouse models, TSLP directly stimulates T H 2 cytokine production leading to inflammation 22 and collagen production leading to skin fibrosis. 23 Genetic studies have identified associations between TSLP polymorphisms and patient susceptibility to AD development, and TSLP protein is overexpressed in the keratinocytes of patients with chronic or acute AD. 10 There is also evidence that TSLP causes pruritus in mice via neurostimulatory effects. 24, 25 In this study, little improvement in pruritus was seen in tezepelumab plus TCS-treated patients. Conversely, dupilumab improved pruritus in a phase 3 study of patients with moderate to severe AD, 14 indicating that IL-4 may play a more fundamental role than TSLP in blocking signals within itch neurons. However, it should be noted that TSLP is upstream of IL-4 10 and therefore should diminish this cytokine, thereby affecting pruritus. It is possible that this inhibition may not be as complete as for IL-4 receptor a blockade by dupilumab. The effect of tezepelumab on pruritus here could have been masked by concomitant high-strength TCS use.
Limitations of this study that may have confounded results included the patient population selected, TCS use, and duration of treatment. Patients were not required to be refractory to TCS at baseline and they received TCS during the run-in and treatment periods. This may have contributed to the placebo effect. A recent AD study revealed that continued TCS use yields substantial responses in placebo-treated patients. 26 In our study, placebotreated patients applied greater TCS amounts during treatment versus tezepelumab-treated patients. All patients applied high-strength TCS during the 2-week run-in period, further blunting any differential effect related to study treatment. It is possible that a tezepelumab monotherapy study might uncover a more definitive efficacy signal. Alternatively, an adjunctive TCS study designed to exclude TCS responders by usng a longer run-in period or a lower potency TCS might demonstrate improved results. Furthermore, only a small number of enrolled patients had severe disease (20%), while most had moderate AD (as determined by IGA score). Given the upstream mechanism of action of TSLP, a longer treatment period may reveal greater improvements in AD symptoms beyond week 12. Finally, the dose used in this study (tezepelumab 280 mg) was selected after the phase 1 study (NCT00757042); we are unsure if complete inhibition of TSLP was demonstrated from our results.
AD is a heterogeneous disease, and understanding this may allow for the identification of patient subgroups that respond better to immune-modifying therapies. We found that DPP-4ehigh, periostin-low, or IgE-high patients demonstrated greater treatment these findings are somewhat unexpected and possibly attributed to confounding concomitant TCS treatment. CCL17/TARC concentration has been reported to decrease after TCS therapy. Therefore, the run-in period where patients received TCS may have led to reported baseline CCL17/TARC concentrations being lower than unreported screening values, identifying a potential responder population. Analyses of biomarker subgroups in this study were not powered, but were prespecified. The incidence of TEAEs was similar between treatment groups, and the safety profile reported was comparable to that described in the phase 2b PATHWAY trial in patients with uncontrolled asthma.
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